Cadence is a New York-based clinical technology company that helps health systems deliver continuous, proactive care to patients with chronic conditions at home. It pairs FDA-cleared connected devices that track vitals with an AI-powered care platform and a 24/7 clinical team, so doctors can catch problems - rising blood pressure, fluid buildup, glucose swings - before they become emergencies. Cadence partners with more than 20 leading U.S. health systems and supports tens of thousands of patients across dozens of states, targeting chronic diseases such as heart failure, hypertension, type 2 diabetes, and COPD.
David Hendren is the Chief Business Officer of QURA, Inc., a Massachusetts medical technology company building an implantable sensor that streams real-time blood-pressure data to patients and physicians. A lawyer by training who has spent more than 25 years working every side of the deal table - venture capitalist, entrepreneur, CEO, board chair, advisor and counsel - he co-founded QURA in 2013 alongside its CEO. He also runs the advisory firm Augmentum Advisors, mentors startups through MassChallenge, sits on a Massachusetts Life Sciences Center review board, and advises VIC Technology Ventures, focusing his career on financing and commercializing healthcare and biomedical innovation.
QURA, Inc. is a preclinical medical-technology company in Massachusetts building a tiny implanted sensor that continuously measures blood pressure and wirelessly transmits medical-grade waveform data to patients and physicians in real time. Its QSmart platform - a vitamin-sized QSense implant paired with software and analytics - aims to replace the occasional cuff reading with always-on monitoring, targeting hypertension, the leading cardiovascular risk factor worldwide. The technology grew out of an earlier wireless implantable pressure sensor developed for glaucoma (intraocular pressure) monitoring.
William G. Hendren, MD, MBA is the co-founder and CEO of QURA, Inc., a Duxbury, Massachusetts medical technology company building the QSmart platform - an implantable biosensor roughly the size of a grain of rice that continuously measures and wirelessly transmits medical-grade blood pressure data in real time. A surgeon trained at Harvard, Mass General, Emory and the Cleveland Clinic, with an MBA and strategic healthcare consulting experience at PwC across the US, Middle East, China and the UK, Hendren is taking aim at hypertension, which he calls the single leading healthcare threat in the world.
Omada Health is a publicly traded (Nasdaq: OMDA) virtual chronic care company that uses behavioral science, connected devices, AI tools, and human care teams to help people manage prediabetes, diabetes, hypertension, high cholesterol, musculoskeletal conditions, and weight - including support for members on GLP-1 medications. Founded in 2011 in San Francisco, it sells to employers, health plans, and pharmacy benefit managers, serving roughly 2,000-plus customers and more than 886,000 members.
Vida Health is a San Francisco-based digital health company that pairs an AI-powered, personalized app with human coaches, dietitians, therapists, and physicians to prevent, manage, and reverse chronic physical and mental conditions. Its virtual cardiometabolic clinic treats obesity, diabetes, hypertension, and the depression and anxiety that travel with them, and is sold to employers and health plans as a clinically validated, cost-managed alternative to fragmented point solutions, including responsible GLP-1 prescribing.
Hello Heart is a Menlo Park-based digital health company exclusively focused on cardiovascular health. Founded in 2013, it offers an AI-powered mobile app paired with a connected blood pressure monitor and smart pill box that helps members understand, track, and improve their heart health. Deployed through employers, health plans, and Medicare Advantage programs, Hello Heart has served users at 150+ Fortune 500 companies and government organizations. Independent peer-reviewed studies - including a JAMA study of 28,000+ participants - show that 84% of high-risk users reduced blood pressure over three years, with average medical cost savings exceeding $1,700 per enrolled member per year. The company has raised $148.5 million in total funding, most recently a $70 million Series D in May 2022.
Maayan Cohen is the Co-Founder and CEO of Hello Heart, a Menlo Park-based digital therapeutics company focused exclusively on cardiovascular health. A former Israeli tank platoon commander turned strategy consultant, she built Hello Heart from a 2013 startup into a platform covering 1.6+ million members across Fortune 500 employers, backed by $148.5M in funding from investors including Khosla Ventures, IVP, and Stripes. Named to CNBC Changemakers 2024 and Inc. Female Founders 500 in 2025, Cohen is recognized for her empathy-driven leadership style - including managing her company from Tel Aviv bomb shelters during the 2023 Israel-Hamas war while providing housing and support for both Israeli and Palestinian staff.
Lark Health is a Mountain View-based digital health company that delivers 24/7, AI-powered nurse coaching for chronic conditions - diabetes, hypertension, weight, behavioral health and tobacco cessation - through a text-message-style app paired with connected devices. Built on cognitive behavioral therapy and used by major payers, Lark scales personalized care to tens of millions of covered lives.